Uncategorized
Alimera, pSivida amend licensing agreement
Alimera Sciences may now seek approval of Iluvien for the secondary indication of posterior uveitis in the European Union, Middle East and Africa, according to a press release from the company.Alimera and pSivida amended a previous agreement, under which “Alimera held the worldwide license from pSivida to sell Iluvien for the treatment of all ocular diseases other than uveitis,” the release said.